## Product: Ilaris

**Generic Name:** canakinumab  
**Manufacturer:** Novartis Pharmaceuticals Canada  
**Indication:** Cryopyrin-Associated Periodic Syndrome (CAPS)

### Summary of Key Dates

- **Submission deemed complete:** 2010-Jul-14
- **Patient group input received:** 2010-Jul-28
- **CADTH Reviewers’ Reports sent to Manufacturer:** 2010-Sep-29
- **Comments from Manufacturer on Reviewers’ Reports Received by CADTH:** 2010-Oct-08
- **CEDAC Meeting:** 2010-Nov-17
- **CEDAC Recommendation Sent to Drug Plans, ACP and Manufacturer:** 2010-Nov-24
- **Embargo Period***: 2010-Dec-08
- **Final Recommendation sent to Drug Plans, ACP, and Manufacturer**: 2011-Jan-26

### Phase 1: Submission deemed complete

- **Target Time (Business Days):** 5 days
- **Target Date:** 2010-Jul-14
- **Actual CDR Date:** 2010-Jul-14
- **Comments:** Submission deemed complete.

### Phase 2: Patient group input received

- **Target Time (Business Days):**
- **Target Date:**
- **Actual CDR Date:**
- **Comments:** Patient group input received.

### Phase 3: CADTH Reviewers’ Reports sent to Manufacturer

- **Target Time (Business Days):** 45 days
- **Target Date:** 2010-Oct-05
- **Actual CDR Date:**
- **Comments:** Reviewer's Reports Sent on 2010-Oct-05.

### Phase 4: Comments from Manufacturer on Reviewers’ Reports Received by CADTH

- **Target Time (Business Days):** 7 days
- **Target Date:** 2010-Oct-15
- **Actual CDR Date:**
- **Comments:** New due date for Manufacturer's Comments on 2010-Oct-15. Manufacturer's Comments received on 2010-Oct-15.

### Phase 5: CEDAC Meeting

- **Target Time (Business Days):**
- **Target Date:**
- **Actual CDR Date:**
- **Comments:**

### Phase 6: CEDAC Recommendation Sent to Drug Plans, ACP and Manufacturer

- **Target Time (Business Days):** 5 days
- **Target Date:** 2010-Nov-24
- **Actual CDR Date:**
- **Comments:**

### Phase 7: Embargo Period***

- **Target Time (Business Days):** 10 days
- **Target Date:** 2010-Dec-08
- **Actual CDR Date:**
- **Comments:**

### Embargo Period***

Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation on 2010-Dec-08. Reconsideration granted on 2010-Dec-14.

### Phase 8(a): Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)

- **Target Time (Business Days):** 5 days
- **Target Date:**
- **Actual CDR Date:**
- **Comments:**

### OR

### Phase 8(b): Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration is made)

- **Target Time (Business Days):** 5 days
- **Target Date:**
- **Actual CDR Date:**
- **Comments:**

### OR

### Phase 8(c): Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)

- **Target Time (Business Days):** 25 days
- **Target Date:**
- **Actual CDR Date:**
- **Comments:**

### Phase 9: Final Recommendation sent to Drug Plans, ACP, and Manufacturer

- **Target Time (Business Days):** 5 days
- **Target Date:**
- **Actual CDR Date:**
- **Comments:** Notice of Final Recommendation issued

---

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.  
** The Formulary review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on [www.cadth.ca](http://www.cadth.ca).  
*** The Recommendation is held in confidence and not acted upon until after CADTH has issued the notice of Final Recommendation. Reflects updates as of Thursday noon.